CHRO — Chromocell Therapeutics Income Statement
0.000.00%
- $6.40m
- $2.63m
Annual income statement for Chromocell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0.2 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 1.55 | 0.839 | 2.32 | 6.86 |
Operating Profit | -1.35 | -0.839 | -2.32 | -6.86 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -0.661 | -0.595 | -2.46 | -7.38 |
Net Income After Taxes | -0.661 | -0.595 | -2.46 | -7.38 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.661 | -0.595 | -2.46 | -7.38 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.661 | -0.595 | -2.46 | -7.38 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.115 | -0.103 | -0.426 | -1.28 |
Dividends per Share |